Reply: Balancing Promise and Evidence: Critical Perspectives on SGLT2 Inhibitors for Cardiotoxicity Prevention.
作者信息
Bhatti Ammar W, Makwana Bhargav, Khadke Sumanth, Dani Sourbha S, Ganatra Sarju
机构信息
Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
出版信息
JACC CardioOncol. 2025 Apr;7(3):316. doi: 10.1016/j.jaccao.2025.01.016. Epub 2025 Mar 18.
Abstract
摘要
相似文献
1
Reply: Balancing Promise and Evidence: Critical Perspectives on SGLT2 Inhibitors for Cardiotoxicity Prevention.回复：权衡前景与证据：关于SGLT2抑制剂预防心脏毒性的批判性观点
JACC CardioOncol. 2025 Apr;7(3):316. doi: 10.1016/j.jaccao.2025.01.016. Epub 2025 Mar 18.
2
Balancing Promise and Evidence: Critical Perspectives on SGLT2 Inhibitors for Cardiotoxicity Prevention.权衡前景与证据：关于SGLT2抑制剂预防心脏毒性的批判性观点
JACC CardioOncol. 2025 Apr;7(3):314-315. doi: 10.1016/j.jaccao.2025.01.017. Epub 2025 Mar 18.
3
Is There a Diabetes-Kidney-Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors.糖尿病-肾脏-心脏之间存在连续关系吗？来自SGLT2抑制剂心血管和肾脏结局临床试验结果的观点。
Front Cardiovasc Med. 2021 Sep 23;8:716083. doi: 10.3389/fcvm.2021.716083. eCollection 2021.
4
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: State-of-the-Art Review.钠-葡萄糖协同转运蛋白2抑制剂的心脏保护和抗癌作用：最新综述
JACC CardioOncol. 2024 Mar 12;6(2):159-182. doi: 10.1016/j.jaccao.2024.01.007. eCollection 2024 Apr.
5
Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis.2型糖尿病合并癌症患者中与钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂治疗相关的心血管结局：一项系统评价和荟萃分析
Diabetol Metab Syndr. 2024 May 22;16(1):108. doi: 10.1186/s13098-024-01354-4.
6
Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment.钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭预防和治疗中的潜在作用。
Diabetol Int. 2020 Jun 11;11(3):252-260. doi: 10.1007/s13340-020-00445-7. eCollection 2020 Jul.
7
Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities.探索SGLT2抑制剂在癌症中的作用：作用机制与治疗机会
Cancers (Basel). 2025 Jan 30;17(3):466. doi: 10.3390/cancers17030466.
8
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.钠-葡萄糖协同转运蛋白 2 抑制剂与接受蒽环类药物治疗患者的心脏结局。
JACC Heart Fail. 2022 Aug;10(8):559-567. doi: 10.1016/j.jchf.2022.03.006. Epub 2022 Jun 8.
9
Adverse cardiovascular and kidney outcomes in people with SARS-CoV-2 treated with SGLT2 inhibitors.接受SGLT2抑制剂治疗的新冠病毒感染者的不良心血管和肾脏结局
Commun Med (Lond). 2024 Sep 11;4(1):179. doi: 10.1038/s43856-024-00599-4.
10
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.从 DAPA-HF 试验中吸取的有关 SGLT2 抑制剂在其他即将完成的大规模试验背景下对心力衰竭事件的获益机制的经验教训。
Cardiovasc Diabetol. 2019 Oct 4;18(1):129. doi: 10.1186/s12933-019-0938-6.
引用本文的文献
1
Effects of SGLT2 Inhibitors on Sleep Apnea Parameters and Cheyne-Stokes Respiration in Patients with Acute Decompensated Heart Failure: A Prospective Cohort Study.钠-葡萄糖协同转运蛋白2抑制剂对急性失代偿性心力衰竭患者睡眠呼吸暂停参数及陈-施呼吸的影响：一项前瞻性队列研究
Biomedicines. 2025 Jun 14;13(6):1474. doi: 10.3390/biomedicines13061474.
本文引用的文献
1
SGLT2i and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction in Patients With Diabetes.钠-葡萄糖协同转运蛋白2抑制剂与糖尿病患者癌症治疗相关心脏功能障碍的一级预防
JACC CardioOncol. 2024 Sep 22;6(6):863-875. doi: 10.1016/j.jaccao.2024.08.001. eCollection 2024 Dec.
2
Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - PILOT trial.恩格列净用于预防心脏毒性：恩格列净预防心脏毒性试验（EMPACARD - PILOT）
Cardiooncology. 2024 Sep 5;10(1):58. doi: 10.1186/s40959-024-00260-y.
3
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: State-of-the-Art Review.钠-葡萄糖协同转运蛋白2抑制剂的心脏保护和抗癌作用：最新综述
JACC CardioOncol. 2024 Mar 12;6(2):159-182. doi: 10.1016/j.jaccao.2024.01.007. eCollection 2024 Apr.
4
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.美国临床内分泌医师协会和美国内分泌学会关于钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与糖尿病酮症酸中毒相关性的立场声明
Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.
Zotero 插件